The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Jan. 06, 2026
Filed:
Nov. 25, 2021
S&k Therapeutics, Suwon-si, KR;
Sangdun Choi, Suwon-si, KR;
Chang Hee Suh, Seoul, KR;
Uisuk Jeong, Suwon-si, KR;
Yangseon Choi, Suwon-si, KR;
Wook-Young Baek, Hwaseong-si, KR;
Kevin Jaesuk Choi, Suwon-si, KR;
Chun Young Im, Daegu, KR;
Doohyun Lee, Daegu, KR;
Nam Hui Kim, Daegu, KR;
Seungyeon Lee, Daegu, KR;
Hyo-Ji Kim, Daegu, KR;
Sang Kyoon Kim, Daegu, KR;
Yoojin Oh, Daegu, KR;
So Young Kim, Daegu, KR;
Ye Ri Han, Daegu, KR;
S&K THERAPEUTICS, Suwon-si, KR;
Abstract
Antagonistic small-molecule compounds having a function of inhibiting endosomal Toll-like receptors (TLRs), more specifically, a small-molecule compound for inhibiting TLR3/7/8/9 signaling pathways, a composition for inhibiting Toll-like receptors, containing the compound; and a composition for preventing or treating autoimmune diseases, inflammatory diseases, or viral diseases are disclosed. The novel compound shows very significant results in a systemic lupus erythematosus animal model by not only preventing TNF-α secretion induced by poly I:C (TLR3 agonist), imiquimod (TLR7 agonist), TL8-506 (TLR8 agonist), or ODN2395 (TLR9 agonist), but also inhibiting the production of inflammatory cytokines. This suggests that the compound is also useful for the prevention or treatment of TLR3, TLR7, TLR8 or TLR9-associated autoimmune diseases, inflammatory diseases and viral diseases.